目的 探討膽康膠囊聯(lián)合頭孢哌酮鈉舒巴坦鈉治療慢性膽囊炎患者的臨床效果。方法 選取2016年7月-2017年7月國藥東風花果醫(yī)院收治的慢性膽囊炎患者175例，隨機分成對照組（87例）和治療組（88例）。對照組患者靜脈滴注注射用頭孢哌酮鈉舒巴坦鈉，4.0 g加入5%葡萄糖注射液100 mL，2次/d。治療組患者在對照組的基礎上口服膽康膠囊，4粒/次，3次/d。兩組患者均治療2周。觀察兩組患者臨床療效，同時比較治療前后兩組患者臨床癥狀積分、VAS評分、SF-36評分、腫瘤壞死因子-α（TNF-α）、β-內啡肽（β-EP）和超氧化物歧化酶（SOD）水平及不良反應情況。結果 治療后，對照組和治療組臨床有效率分別為82.76%和95.45%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者右腹部疼痛，腹脹，惡心、厭油等癥狀積分均顯著下降（P<0.05），且治療組患者各項癥狀積分比對照組降低的更明顯（P<0.05）。治療后，兩組患者VAS比治療前均顯著降低（P<0.05），SF-36評分顯著升高（P<0.05），同時治療組患者VAS和SF-36評分比對照組患者改善更明顯（P<0.05）。治療后，兩組患者TNF-α和β-EP水平顯著降低（P<0.05），SOD血清水平顯著升高（P<0.05），同時治療組患者TNF-α、β-EP和SOD血清水平明顯優(yōu)于對照組患者（P<0.05）。治療期間，對照組患者不良反應發(fā)生率為18.39%，顯著高于治療組的5.68%，兩組患者比較差異具有統(tǒng)計學意義（P<0.05）。結論 膽康膠囊聯(lián)合頭孢哌酮鈉舒巴坦鈉治療慢性膽囊炎患者臨床療效顯著，并可改善患者的臨床癥狀，降低不良反應發(fā)生率。

Objective To discuss clinical effect of Dankang Capsules combined with cefoperazone sodium and sulbactam sodium in treatment of chronic cholecystitis. Methods Patients (175 cases) with chronic cholecystitis in Sinopharm Dongfeng Huaguo Hospital from July 2016 to July 2017 were randomly divided into control (87 cases) and treatment (88 cases) groups. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 4.0 g added into 5% glucose injection 100 mL, twice daily. Patients in the treatment group were po administered with Dankang Capsules on the basis of the control group, 4 grains/times, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom, VAS and SF-36 scores, the TNF-alpha, beta -EP and SOD levels, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.76% and 95.45% respectively, and there were differences between two groups (P<0.05). After treatment, the right abdominal pain, abdominal distension, nausea and disgust edible oil scores in two groups were significantly decreased (P<0.05), and these the clinical symptom scores in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the VAS scores in two groups were significantly decreased (P<0.05), SF-36 scores were significantly increased (P<0.05), and the VAS and SF-36 scores in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the TNF-α and β-EP levels in two groups were significantly decreased (P<0.05), SOD levels were significantly increased (P<0.05), and these indicators in the treatment group after treatment were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the control group was 18.39%, which was significantly higher than 5.68% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Dankang Capsules combined with cefoperazone sodium and sulbactam sodium has significant clinical efficacy in treatment of chronic cholecystitis, and can improves the clinical symptom, reduce the incidence of adverse reactions.